Ephrin-A5 (AL-1)

A GLYCOINOSITOL PHOSPHOLIPID MEMBRANE ANCHOR containing ephrin found in developing tectum. It has been shown to mediate the bundling of cortical axons and repel the axonal growth of retinal ganglia axons. It is found in a variety of adult tissues of BRAIN; HEART; and KIDNEY.

Also Known As:

Networked: 64 relevant articles (5 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Wang, Yuqiang: 5 articles (01/2020 - 07/2014)
2.	Xu, Lipeng: 5 articles (01/2020 - 07/2014)
3.	Yu, Pei: 5 articles (01/2020 - 08/2009)
4.	Zhou, Renping: 5 articles (02/2016 - 10/2008)
5.	Cheng, Catherine: 4 articles (01/2022 - 01/2011)
6.	Zhang, Zaijun: 4 articles (01/2020 - 07/2014)
7.	Son, Alexander I: 3 articles (02/2016 - 10/2008)
8.	Sun, Yewei: 3 articles (01/2016 - 07/2014)
9.	Lackmann, Martin: 3 articles (05/2007 - 03/2002)
10.	Shan, Luchen: 2 articles (01/2020 - 01/2016)

Related Diseases

1.	Colitis 01/15/2020 - "AL-1 protected the intestinal barrier function in DSS-induced colitis mice. " 01/01/2019 - "In conclusion, AL-1 alleviated DSS-induced murine colitis by inhibiting activation of the NF-κB and MAPK signaling pathways. " 01/01/2019 - "However, the effect of AL-1 on DSS-induced murine colitis and the underlying mechanisms are yet unknown. " 01/01/2016 - "AL-1 attenuated the expression of p-p65, p-IκBα and COX-2 in the colitis mice. " 01/01/2019 - "Our recent study has demonstrated that a novel andrographolide derivative, AL-1, ameliorated TNBS-induced colitis in mice. "
2.	Acute Lung Injury 01/01/2022 - "Andrographolide Derivative AL-1 Ameliorates LPS-induced Acute Lung Injury by Inhibiting NLRP3 Inflammasome and Lung Permeability."
3.	Parkinson Disease (Parkinson's Disease) 07/01/2014 - "In the present work, the neuroprotective effect of AL-1 was investigated in vitro and in a mouse model of the Parkinson's disease (PD). " 07/01/2014 - "Neuroprotective effects of the andrographolide analogue AL-1 in the MPP⁺/MPTP-induced Parkinson's disease model in vitro and in mice." 07/01/2014 - "In a mouse model of Parkinson's disease, AL-1 rescued 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced loss of tyrosine hydroxylase (TH)-positive neurons, improved the behavioral impairment, and elevated the striatal levels of dopamine and its metabolites 3,4-dihydroxyphenylacetic acid. "
4.	Human Influenza (Influenza) 08/01/2009 - "AL-1 was effective against avian influenza A (H9N2 and H5N1) and human influenza A H1N1 viruses in vitro, with the 50% effective concentrations ranging from 7.2 to 15.2 microM and the selective indexes ranging from 51 to 109. " 08/01/2009 - "The administration of AL-1 by oral gavage to mice infected with avian influenza A/Chicken/Guangdong /96 (H9N2), A/Duck/Guangdong/99 (H5N1), and human influenza A/PR/8/34 (H1N1) viruses greatly reduced the death rate, prolonged life, inhibited lung consolidation, and reduced viral titers in the lung. " 08/01/2009 - "With potent antiviral activity and a potentially new mechanism of action, AL-1 may warrant further evaluation as a possible therapy for influenza."
5.	Influenza in Birds (Avian Flu) 08/01/2009 - "AL-1 was effective against avian influenza A (H9N2 and H5N1) and human influenza A H1N1 viruses in vitro, with the 50% effective concentrations ranging from 7.2 to 15.2 microM and the selective indexes ranging from 51 to 109. " 08/01/2009 - "The administration of AL-1 by oral gavage to mice infected with avian influenza A/Chicken/Guangdong /96 (H9N2), A/Duck/Guangdong/99 (H5N1), and human influenza A/PR/8/34 (H1N1) viruses greatly reduced the death rate, prolonged life, inhibited lung consolidation, and reduced viral titers in the lung. "

Related Drugs and Biologics

1.	andrographolide
2.	Inflammasomes
3.	Peroxisome Proliferator-Activated Receptors (PPAR)
4.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
5.	3,4-Dihydroxyphenylacetic Acid
6.	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)
7.	Dopamine (Intropin)
8.	Dextrans (Dextran)
9.	sodium sulfate (sodium bisulfate)
10.	Ligands

Related Therapies and Procedures

1.	Lenses
2.	Neoadjuvant Therapy
3.	Therapeutics
4.	Oral Administration